F. Hoffmann-La Roche Ltd.

DUBLIN, Sept. 26, 2023 /PRNewswire/ -- The "Blood Gas and Electrolyte Analyzers - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Blood Gas and Electrolyte Analyzers Market to Reach $1.2 Billion by 2030 The global Blood Gas and Electrolyte Analyzers market is projected to grow substantially, from an estimated value of US$814.7 Million in 2022 to a revised size of approximately US$1.2 Billion by 2030. This represents a Compound Annual Growth Rate (CAGR) of 5.2% over the forecast period of 2022-2030. The market report provides a detailed analysis, covering annual sales trends for different types of analyzers such as Portable, Benchtop, and Combined Analyzers. The Portable segment alone is expected to grow at a CAGR of 5.8%, reaching an estimated US$823.6 Million by the end of 2030. Meanwhile, the Benchtop segment is forecasted to grow at a CAGR of 3.9% over the next eight years. Geographically, the U.S. market for Blood Gas and Electrolyte Analyzers stands at an estimated US$234.9 Million in 2022. China, being the world's second-largest economy, is expected to see impressive growth with a projected market size of US$145.5 Million by 2030, at a CAGR of 6.7% from 2022 to 2030. Other significant markets include Japan and Canada, forecasted to grow at CAGRs of 4.3% and 4.4% respectively over the same period. In Europe, Germany is expected to grow at a CAGR of approximately 4.9%. This comprehensive market analysis provides invaluable insights for stakeholders in the healthcare industry, enabling them to make well-informed decisions. Factors such as clinical applications, technological advancements, and geographic growth trends significantly influence the market dynamics, offering diverse opportunities for market players. What`s New? Special discussions on the global economic climate and market sentiment Coverage on global competitiveness and key competitor percentage market shares Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and trademarked research platform Complimentary updates for one year Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Life-Saving Interventions for COVID-19 Patients Drive Importance of Blood Gas & Electrolyte Analyzers Percentage of people with COVID-19 who were admitted to the ICU in the United States from January 22 to May 30, 2020, by age* Industry Witnesses Inflow of Sophisticated Solutions Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2021 (E) Blood Gas and Electrolyte Analyzers: An Introduction Types of Analyzers Fundamentals of Blood Gases and Blood Gas Testing Blood Gas Parameters and their Significance Outlook Point-of-Care Analyzers Gain Significance Hurdles to Overcome Competition Market Share of Leading Players in Global Blood Gas and Electrolyte Analyzers Market: 2019 Recent Industry Activity World Brands MARKET TRENDS & DRIVERS Decentralized Testing Gains Traction Technology Advancements: Cornerstone for Market Growth Select New Devices Advanced Sensors Give Way to Modern Devices Blood Gas Testing Becomes Commonplace in Critical Care Benchtop Makers Cash in on the Lucrative POC Market Advanced Solutions for Point-of-Care & Critical Care Settings Integration with LIS and EMR Widens Functionality Miniaturised Blood Gas Analysers Gain Traction Increasing Prevalence of Chronic Disorders and Patient admissions Fuels Market Growth Assessment of Various Conditions Based on Blood Gas Testing Alarming Levels of Diabetes Incidence Worldwide Drives Demand World Diabetes and Population Statistics (2019, 2030 & 2045) World Diabetes Prevalence (2000-2019) Rise in CVD Incidence Spurs Demand Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others Global Annual Medical Cost of CVD in US$ Billion (2010-2030) Rising Cancer Incidence and Ensuing Rise in Critical Care Admissions Create Need for Blood Gas and Electrolyte Analyzers Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 Number of New Cancer Cases and Deaths (in Million) by Region for 2018 Rise in Prevalence of COPD Augments Demand EXHIBIT : Global Prevalence of COPD by Age Group: Percentage of Men and Women Affected by the Condition Rising Aging Population: Principal Driver for the BGA Market Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Healthcare Cost-Cutting Trend Promotes Innovations World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023 FOCUS ON SELECT PLAYERS (Total 53 Featured) Beckman Coulter, Inc. Danaher Corporation ARKRAY, Inc. F. Hoffmann-La Roche AG Abbott Point of Care, Inc. EKF Diagnostics Holdings PLC Abaxis, Inc. Convergent Technologies GmbH & Co. KG EDAN Instruments, Inc. Accurex Biomedical Pvt. Ltd. BioCare Corporation BIOBASE Fortress Diagnostics ARI Medical Technology Co., Ltd. Erba Mannheim For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN, Sept. 25, 2023 /PRNewswire/ -- The "Hemoglobin A1c Testing Devices and Kits Market" report has been added to ResearchAndMarkets.com's offering. The global Hemoglobin A1c Testing Devices & Kits Market was valued at $1.9 billion in 2022, and it is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.2% to reach $3.2 billion by 2028. This report provides a comprehensive study of the market, including the different types of Hemoglobin A1c Testing Devices & Kits products, technology, and historical and current market revenues. Market Segmentation: The report segments the Hemoglobin A1c Testing Devices & Kits Market based on various factors: Technology: It categorizes products by technology. End User: It classifies products based on the end user, such as hospitals, clinics, laboratories, etc. Geographic Regions: The global market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Key Companies Mentioned: The report profiles major players in the Hemoglobin A1c Testing Devices & Kits Market, including: Abbott Arkray Inc. Bayer AG Bio-Rad Laboratories Inc. Danaher Ekf Diagnostics Holdings plc F. Hoffmann-La Roche AG Lumiradx Meril Life Sciences Private. Ltd. Osang Healthcare Co. Ltd. Siemens Healthcare GmbH Sinocare Inc. Thermo Fisher Scientific Inc. Trinity Biotech plc Wuxi Biohermes Biomedical Technology Co. Ltd. Xiamen Biotime Biotechnology Co. Ltd. Report Highlights: The report provides an overview of the global market landscape related to Hemoglobin A1c Testing Devices & Kits. It offers an in-depth analysis of global market trends, including historical revenue data for 2020-2022, estimated figures for 2023, and forecasts for 2023-2028, with projections of Compound Annual Growth Rates (CAGRs). The current market size and revenue growth prospects specific to Hemoglobin A1c Testing Devices & Kits are evaluated, along with a comprehensive market share analysis categorized by technology, end user, and geographical region. The report explores the upcoming market potential for Hemoglobin A1c test devices and kits, and areas of focus to forecast this market into various segments and sub-segments. It provides in-depth information regarding the major factors influencing market progress, including benefits, industry-specific challenges, growth trends, upcoming technologies, regulations, prospects, and contributions to the overall market. The role and importance of Environmental, Social, and Governance (ESG) in the Hemoglobin A1c Testing Devices & Kits market are discussed, including consumer attitudes, risks, opportunity assessment, and ESG practices in the industry. Major stakeholders are identified, and their company competitive landscape is analyzed based on recent developments, key financials, segmental revenues, and operational integration. Detailed profiles of leading market participants, including their respective businesses, are presented. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Chapter 4 Market Dynamics Market Dynamics Drivers Restraints Opportunities Chapter 5 Global Market for Hemoglobin A1C Testing Devices and Kits by Technology Chapter 6 Global Market for Hemoglobin A1C Testing Devices and Kits by End-user Chapter 7 Global Market for Hemoglobin A1C Testing Devices and Kits by Region Chapter 8 Sustainability in the Hemoglobin A1C Testing Devices and Kits Industry: An Esg Perspective Chapter 9 Emerging Technology in the Diabetes Diagnosis Industry: Qualitative Perspective Chapter 10 M&A and Venture Funding Outlook in the Market Chapter 11 Competitive Landscape Chapter 12 Company Profiles Chapter 13 Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The "Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's offering. Companion Diagnostics are poised to revolutionize the diagnostics industry, shifting from laboratory settings to clinical applications. Leading the charge, especially in the realm of immune-oncology, these advancements are receiving a warm welcome from the FDA, opening doors to the diagnostic technology of the future. Discover the latest insights into this pivotal market. Will Personalized Companion Diagnostics Become the New Norm? The diagnostic landscape is evolving rapidly, as key players collaborate with pharmaceutical counterparts to seize novel business opportunities. Some innovators are already at the forefront of this dynamic market, offering a wealth of possibilities. Diagnostic companies are strategically aligning themselves with the advancing science, while the cost of molecular diagnostics continues to decrease. In the report titled "Companion Diagnostic Markets: The Future of Diagnostics," analysts and planners gain access to invaluable data. This comprehensive resource includes extensive information, including the complete United States Medicare Fee Payment Schedules, offering a detailed analysis of New Nucleic Acid Test Pricing. It aids in forecasting demand for emerging testing regimes and technologies, guiding research investment decisions. Furthermore, it provides precise growth projections and market size estimates tailored to your specific area of interest, all without additional charges. Existing laboratories and hospitals can directly utilize this information to forecast and plan for the growth of clinical facilities, with complimentary assistance provided for maximizing its benefits. The report offers detailed breakdowns for 18 countries and 4 regions, with the option for purchasers to access in-depth analysis for any specific country or area worldwide. Key Topics Covered: 1 Market Guides 2 Introduction and Market Definition 3 Market Overview 3.1 Players in a Dynamic Market 3.1.1 Academic Research Lab 3.1.2 Diagnostic Test Developer 3.1.3 Instrumentation Supplier 3.1.4 Chemical/Reagent Supplier 3.1.5 Pathology Supplier 3.1.6 Independent Clinical Laboratory 3.1.7 Public National/regional Laboratory 3.1.8 Hospital Laboratory 3.1.9 Physicians Office Lab (POLS) 3.1.10 Audit Body 3.1.11 Certification Body 3.2 Personalized Medicine and Companion Diagnostics 3.2.1 Basics 3.2.2 Method 3.2.3 Disease risk assessment 3.2.4 Applications 3.2.5 Diagnosis and intervention 3.2.5.1 Companion Diagnostics 3.2.6 Drug development and usage 3.2.7 Respiratory proteomics 3.2.8 Cancer genomics 3.2.9 Population screening 3.2.10 Challenges 3.2.11 Regulatory oversight 3.2.12 Intellectual property rights 3.2.13 Reimbursement policies 3.2.14 Patient privacy and confidentiality 3.3 Chromosomes, Genes and Epigenetics 3.3.1 Chromosomes 3.3.2 Genes 3.3.3 Epigenetics 3.4 Cancer Genes 3.4.1 Germline vs Somatic 3.4.2 Changing Clinical Role 3.5 Structure of Industry Plays a Part 3.5.1 New Pharmaceutical Funding Market 3.5.2 Economies of Scale 3.5.2.1 Hospital vs. Central Lab 3.5.3 Physician Office Labs 3.5.4 Physicians and POCT 4 Market Trends 4.1 Factors Driving Growth 4.1.1 Level of Care. 4.1.2 Immuno-oncology. 4.1.3 Liability. 4.1.4 The Aging World 4.2 Factors Limiting Growth 4.2.1 State of knowledge. 4.2.2 Genetic Blizzard. 4.2.3 Protocol Resistance. 4.2.4 Regulation and coverage. 4.3 Instrumentation, Automation and Diagnostic Trends 4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point Of Care 4.3.3 Instruments Key to Market Share 4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing 4.3.8 Whole Genome Sequencing, A Brave New World 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 5 Companion Diagnostics Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 Agilent CDx Assay IVDR Certified 5.3 ARUP Laboratories Gets Approval for Gene Therapy CDx 5.4 Guardant Health Gets Medicare Coverage for Liquid Biopsy Test 5.5 Amoy Dx PLC Panel Gets Approval in Japan as CDx 5.6 UnitedHealthcare Expands Precision Oncology Dx Coverage 5.7 JaxBio to Create Array-Based Cancer Tests 5.8 Agilent, Qiagen Win FDA Approvals Companion Diagnostics 5.9 Navignostics Using Single-Cell Spatial Proteomics 5.10 HMNC Brain Health to Develop Companion Diagnostics 5.11 Propath UK, Nucleai Partner on Spatial Proteomics 5.12 Becton Dickinson, Labcorp Collaborate for Flow Cytometry-Based CompanionDiagnostics 5.13 Almac, AstraZeneca Strike CDx Development Pact 5.14 Avalon GloboCare, Lu Daopei Hematology Institute to Develop Cell Therapy CDx 5.15 Burning Rock Secures Lung Cancer NGS Test Approval in China 5.16 TenSixteen Bio Developing Drugs, Companion NGS Tests 5.17 Guardant Health Plans New Comprehensive Assay 5.18 Thermo Fisher, Oncocyte Ink Comarketing Deal for Cancer IVDs 5.19 Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test 5.20 Japanese Approves Thermo Fisher Scientific Oncomine Assay as CDx 5.21 Promega, Henlius to Develop Microsatellite Instability CDx for Cancer Drug 5.22 Natera Aims to Lead Market in Solid Tumor Adjuvant CDx 5.23 Oncocyte Details Expansions Plans 5.24 Agilent Acquires Resolution Biosciences 5.25 Qiagen, Inovio Expand CDx Partnership 5.26 AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance 5.27 NeoGenomics to Grow Through CDx Agreements, Acquisitions 5.28 Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction 5.29 Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform 5.30 FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies 5.31 Promega to Develop MSI Assay as CDx 5.32 Guardant Health to Develop CDx for Janssen 5.33 Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx 5.34 FDA Approval for FoundationOneCDx 5.35 FDA finalizes CDx Guidance 5.36 QIAGEN Launches CDx Therascreen BRAF Test 6 Profiles of Key Players 6.1 10x Genomics, Inc. 6.2 Abbott Laboratories 6.3 AccuraGen Inc. 6.4 Adaptive Biotechnologies 6.5 Aethlon Medical 6.6 Agilent/Dako 6.7 Anchor Dx 6.8 ANGLE plc 6.9 ARUP Laboratories 6.10 AVIVA Systems Biology 6.11 Baylor Miraca Genetics Laboratories 6.12 Beckman Coulter Diagnostics 6.13 Becton, Dickinson and Company 6.14 BGI Genomics Co. Ltd 6.15 Bioarray Genetics 6.16 Biocartis 6.17 Biocept, Inc. 6.18 Biodesix Inc. 6.19 BioFluidica 6.20 BioGenex 6.21 BioIVT 6.22 Biolidics Ltd 6.23 bioMerieux Diagnostics 6.24 Bioneer Corporation 6.25 Bio-Rad Laboratories, Inc 6.26 Bio-Reference Laboratories 6.27 Bio-Techne 6.28 Bioview 6.29 Bolidics 6.30 Boreal Genomics 6.31 Bristol-Myers Squibb 6.32 Burning Rock 6.33 Cardiff Oncology 6.34 Caris Molecular Diagnostics 6.35 Castle Biosciences, Inc. 6.36 CellCarta 6.37 CellMax Life 6.38 Cepheid (Danaher) 6.39 Charles River Laboratories 6.40 Circulogene 6.41 Cizzle Biotech 6.42 Clinical Genomics 6.43 Cytolumina Technologies Corp. 6.44 Datar Cancer Genetics Limited 6.45 Diagnologix LLC 6.46 Diasorin S.p.A. 6.47 Dxcover 6.48 Element Biosciences 6.49 Enzo Biochem 6.50 Epic Sciences 6.51 Epigenomics AG 6.52 Eurofins Scientific 6.53 Fabric Genomics 6.54 Fluxion Biosciences 6.55 Freenome 6.56 FUJIFILM Wako Diagnostics 6.57 Fyr Diagnostics 6.58 GeneFirst Ltd. 6.59 Genetron Holdings 6.60 GenomOncology 6.61 GILUPI Nanomedizin 6.62 Guardant Health 6.63 HansaBiomed 6.64 HeiScreen 6.65 Helomics 6.66 HTG Molecular Diagnostics 6.67 iCellate 6.68 Illumina 6.69 Incell Dx 6.70 Inivata 6.71 INOVIQ 6.72 Integrated Diagnostics 6.73 Invitae Corporation 6.74 Invivogen 6.75 Invivoscribe 6.76 Janssen Diagnostics 6.77 Lunglife AI Inc 6.78 MDNA Life SCIENCES, Inc. 6.79 MDx Health 6.80 Menarini Silicon Biosystems 6.81 Mesa Laboratories, Inc. 6.82 Millipore Sigma 6.83 Miltenyi Biotec 6.84 miR Scientific 6.85 Myriad Genetics/Myriad RBM 6.86 NantHealth, Inc. 6.87 Natera 6.88 NeoGenomics 6.89 NGeneBio 6.90 Novogene Bioinformatics Technology Co., Ltd. 6.91 Oncocyte 6.92 OncoDNA 6.93 Ortho Clinical Diagnostics 6.94 Oxford Nanopore Technologies 6.95 PamGene 6.96 Panagene 6.97 Perkin Elmer (Revvity) 6.98 Personal Genome Diagnostics 6.99 Personalis 6.100 Precipio 6.101 Precision Medicine Group 6.102 PrecisionMed 6.103 Predicine 6.104 Promega 6.105 Qiagen 6.106 Rarecells SAS 6.107 RareCyte 6.108 Roche Molecular Diagnostics 6.109 Screencell 6.110 Sema4 Holdings 6.111 Sense Biodetection 6.112 Siemens Healthineers 6.113 simfo GmbH 6.114 Singlera Genomics Inc. 6.115 Singular Genomics 6.116 Singulomics 6.117 SkylineDx 6.118 Standard BioTools 6.119 Stilla Technologies 6.120 Sysmex Inostics 6.121 Tempus Labs, Inc. 6.122 Thermo Fisher Scientific Inc. 6.123 Todos Medical 6.124 Ultima Genomics 6.125 Veracyte 6.126 Volition 6.127 Vortex Biosciences 6.128 Vyant Bio 7 The Global Market for Companion Diagnostics 8 Global Companion Diagnostic Markets - By Application 9 Global Companion Diagnostic Markets - Funding Source 10 Global Companion Diagnostic Markets - Technology 11 Appendices For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets